Company Overview of AstraZeneca Canada Inc.
AstraZeneca Canada Inc. operates as a biopharmaceutical company that engages in discovering, developing, manufacturing, marketing, and selling prescription medicines in Canada. It focuses on various therapeutic areas, such as cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory. The company was founded in 1999 and is based in Mississauga, Canada. Astrazeneca Canada Inc. operates as a subsidiary of AstraZeneca PLC.
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Founded in 1999
Key Executives for AstraZeneca Canada Inc.
Chief Executive Officer and President
Chief Financial Officer and Vice President of Finance & Information Technology
Vice President of Human Resources & Communications
Vice President of Strategic Planning & Commercial Operations
Compensation as of Fiscal Year 2016.
AstraZeneca Canada Inc. Key Developments
TAGRISSO™ (osimertinib) Approves by Health Canada as Treatment for Patients with Locally Advanced or Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Jul 11 16
AstraZeneca Canada announced that Health Canada has approved TAGRISSO™ (osimertinib) once-daily tablets for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. As a first-in-class treatment, TAGRISSO has been granted the Health Canada Notice of Compliance with Conditions (NOC/c), based on promising evidence of clinical efficacy data, pending the results of additional trials to verify its clinical benefit. TAGRISSO is the first and only approved medicine indicated for patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. As a targeted cancer therapy, TAGRISSO is an EGFR-TKI that acts on both the sensitizing EGFR mutation involved in cancer development and T790M, a genetic mutation that makes tumours resistant to existing treatment with EGFR-TKIs. This advancement in therapy allows patients to remain on an oral EGFR-TKI medication longer, delaying the need for chemotherapy. Tumour cells almost always develop resistance to treatment, to disease progression. Nearly two-thirds of NSCLC patients who are EGFR mutation-positive and experience disease progression after being treated with an EGFR-TKI develop the T790M resistance mutation, for which there have been limited treatment options. On average, 57 Canadians die from lung cancer every day – that's more than 20,000 each year. In fact, more people die from lung cancer than breast cancer, colorectal cancer and prostate cancer combined. NSCLC is the most common form of lung cancer and accounts for 85 to 90% of all lung cancers in Canada. Often diagnosed in late stage, fewer than 17% of patients diagnosed with NSCLC will live more than five years following diagnosis. Genetic Mutations in NSCLC: Ethnicity can increase risk for genetic mutations in NSCLC. In Caucasian populations, 10 to 15% of all NSCLC diagnoses are EGFR mutation-positive, but this climbs to 30 to 40% in people of Asian background with NSCLC. Also, NSCLC patients with the EGFR T790M mutation are more likely to be female and to have never smoked. TAGRISSO is part of a new era of medical advances that demonstrate the promise of 'personalized medicine' or 'targeted therapy', which is the tailoring of medical treatment to the individual characteristics, needs and preferences of each patient. Biomarker-based treatments differ from standard, one-size-fits-all therapy. Treatment response is much more predictable and as a result those who are most likely to benefit are treated while avoiding additional treatment burden and cost for those who would not benefit. Testing for the EGFR T790M resistance mutation should be conducted using a validated methodology, prior to starting treatment with TAGRISSO, after a patient has progressed on TKI treatment. Testing currently involves collecting samples of tumour tissue from patients by biopsy. Canadian labs are in the process of validating plasma-based EGFR T790M mutation detection, which would allow patients to be assessed with a simple blood test.
AstraZeneca Canada Announces Availability of DUAKLIR GENUAIR in Canada for Treatment of Chronic Obstructive Pulmonary Disease
Oct 29 15
AstraZeneca Canada announced that DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate 400/12 µg) is now available in Canada for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. DUAKLIR offers a unique combination of a long-acting muscarinic antagonist (LAMA), aclidinium bromide and fast long acting beta2-agonist (LABA), formoterol fumarate, administered through the GENUAIR device. Approximately 90% of COPD patients experience symptoms such as breathlessness and coughing during at least one part of the day, and as many as 50% experience symptoms around-the-clock. Research has shown that the GENUAIR device is preferred by patients when compared to other devices commonly used for COPD. The inhaler is a pre-loaded, multi-dose dry powder inhaler (DPI) that combines positive feedback mechanisms with the DUAKLIR treatment, which relaxes the muscles of the airways, helping to keep them open, allowing the patient to breathe more easily. By controlling the frequency of daily respiratory symptoms, DUAKLIR GENUAIR can help alleviate patient anxiety and stress related to dosing and symptom management. The device includes two physical mechanisms—a 'click' sound and a colour indicator change, which help reassure patients that their twice-a-day dosages are administered correctly.
AstraZeneca Canada Inc. Launches New FluMist Quadrivalent Flu Vaccine
Oct 26 15
AstraZeneca Canada Inc. announced the approval and availability of FluMist Quadrivalent (FluMist), the only needle-free flu vaccine available in Canada that protects against two A strains of the flu, and for the first time, two B strains.2 FluMist has been shown to be 48% more effective in children ages two to 17 than the traditional flu shot across all strains. FluMist addresses the growing issue of mismatched influenza strains. By adding a second B virus to the traditional trivalent vaccine, the likelihood of matching the major circulating B strain increases. In fact, Canada'sNational Advisory Committee on Immunization (NACI) recommends the use of a quadrivalent flu vaccine for the 2015-2016 flu season. FluMist, a Live Attenuated Influenza Vaccine (LAIV), is administered through the nose, where the flu virus typically enters the body. This method closely mimics natural infection which contributes to its superior efficacy when compared to the traditional flu shot. NACI also recommends a LAIV vaccine like FluMist for children aged two to 17 compared to a traditional flu shot. FluMist is available through nearly all provincial and territorial immunization programs. Each flu season, 3.5 to 7 million Canadians (10% to 20% of the population) will be infected with the flu, and more than 12,000 Canadians are expected to visit the hospital because of the flu and related illnesses. By vaccinating each flu season, Canadians who cannot receive a flu vaccine including infants, seniors and those with compromised or fragile immune systems may also be protected through herd immunity. Herd immunity is important especially in schools and among children, in senior or long-term care facilities and in those aged 65 and older.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|